Literature DB >> 20884713

Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.

Victor R Gordeuk1, Caterina P Minniti, Mehdi Nouraie, Andrew D Campbell, Sohail R Rana, Lori Luchtman-Jones, Craig Sable, Niti Dham, Gregory Ensing, Josef T Prchal, Gregory J Kato, Mark T Gladwin, Oswaldo L Castro.   

Abstract

BACKGROUND: While in adults with sickle cell disease an elevation of tricuspid regurgitation velocity is associated with increased mortality, the importance of this finding in children has not been established. The role of intravascular hemolysis in the development of this complication is controversial. DESIGN AND METHODS: We conducted a prospective, longitudinal, multi-center study of 160 individuals aged 3-20 years with hemoglobin SS, performing baseline and follow-up determinations of clinical markers, six-minute walk distance less than tricuspid regurgitation velocity and E/Etdi ratio by echocardiography.
RESULTS: At baseline, 14.1% had tricuspid regurgitation velocity of 2.60 m/sec or over, which suggests elevated systolic pulmonary artery pressure, and 7.7% had increased E/Etdi, which suggests elevated left ventricular filling pressure. Over a median of 22 months, baseline elevation in tricuspid regurgitation velocity was associated with an estimated 4.4-fold increase in the odds of a 10% or more decline in age-standardized six-minute-walk distance (P = 0.015). During this interval, baseline values above the median for a hemolytic component derived from four markers of hemolysis were associated with a 9.0-fold increase in the odds of the new onset of elevated tricuspid regurgitation velocity (P = 0.008) and baseline E/Etdi elevation was associated with an estimated 6.1-fold increase in the odds (P = 0.039). In pathway analysis, higher baseline hemolytic component and E/Etdi predicted elevated tricuspid regurgitation velocity at both baseline and follow up, and these elevations in turn predicted decline in six-minute-walk distance.
CONCLUSIONS: Further studies should define the long-term risks of elevated tricuspid regurgitation velocity in childhood and identify potential interventions to prevent increased pulmonary artery pressure and preserve function.

Entities:  

Mesh:

Year:  2010        PMID: 20884713      PMCID: PMC3012762          DOI: 10.3324/haematol.2010.030767

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  37 in total

1.  Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography.

Authors:  Miguel A Quiñones; Catherine M Otto; Marcus Stoddard; Alan Waggoner; William A Zoghbi
Journal:  J Am Soc Echocardiogr       Date:  2002-02       Impact factor: 5.251

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 3.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

4.  Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years.

Authors:  Margaret T Lee; Tania Small; Muhammad A Khan; Erika B Rosenzweig; Robyn J Barst; Gary M Brittenham
Journal:  Br J Haematol       Date:  2009-06-25       Impact factor: 6.998

5.  Cardiac involvement in thalassemia intermedia: a multicenter study.

Authors:  A Aessopos; D Farmakis; M Karagiorga; E Voskaridou; A Loutradi; A Hatziliami; J Joussef; J Rombos; D Loukopoulos
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

6.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Prospective evaluation of haemoglobin oxygen saturation at rest and after exercise in paediatric sickle cell disease patients.

Authors:  Andrew Campbell; Caterina P Minniti; Mehdi Nouraie; Manuel Arteta; Sohail Rana; Onyinye Onyekwere; Craig Sable; Gregory Ensing; Niti Dham; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

8.  Prolonged QTc interval in children and young adults with sickle cell disease at steady state.

Authors:  Robert I Liem; Luciana T Young; Alexis A Thompson
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

9.  Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering.

Authors:  Hanane A Dahoui; Munya N Hayek; Paul J Nietert; Mariam T Arabi; Samar A Muwakkit; Raya H Saab; Abdallah N Bissar; Nidal M Jumaa; Fadi S Farhat; Ibrahim A Dabbous; Fadi F Bitar; Miguel R Abboud
Journal:  Pediatr Blood Cancer       Date:  2010-03       Impact factor: 3.167

10.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Authors:  Oswaldo Castro; Mohammed Hoque; Bernice D Brown
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  29 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Vascular risk assessment in patients with sickle cell disease.

Authors:  Claudia R Morris
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

Review 3.  Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Authors:  Victor R Gordeuk; Oswaldo L Castro; Roberto F Machado
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

4.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

5.  Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia.

Authors:  Xu Zhang; Kiarri N Kershaw; Caterina P Minniti; Andrew Campbell; Sohail R Rana; Deepika S Darbari; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory Ensing; Manuel Arteta; James G Taylor; Lewis L Hsu; Sergei Nekhai; Victor R Gordeuk
Journal:  Blood Adv       Date:  2020-07-28

6.  TRV: a physiological biomarker in sickle cell disease.

Authors:  Gregory J Kato
Journal:  Pediatr Blood Cancer       Date:  2011-12-16       Impact factor: 3.167

Review 7.  Cardiovascular complications in patients with sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

9.  Echocardiographic Screening of Cardiovascular Status in Pediatric Sickle Cell Disease.

Authors:  Kiona Y Allen; Shannon Jones; Tannoa Jackson; Grace DeCost; Paul Stephens; Brian D Hanna; Meryl S Cohen; Kim Smith-Whitley; Laura Mercer-Rosa; Shobha S Natarajan
Journal:  Pediatr Cardiol       Date:  2019-09-21       Impact factor: 1.655

Review 10.  Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Authors:  Santosh L Saraf; Robert E Molokie; Mehdi Nouraie; Craig A Sable; Lori Luchtman-Jones; Gregory J Ensing; Andrew D Campbell; Sohail R Rana; Xiao M Niu; Roberto F Machado; Mark T Gladwin; Victor R Gordeuk
Journal:  Paediatr Respir Rev       Date:  2013-11-15       Impact factor: 2.726

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.